BRCA1 and breast cancer: We did, however, not find a predictive value of the BRCA1-like status, as is consistent with preclinical findings of Quinn et al. who observed no differential dose-response effect of capecitabine in BRCA1-mutated compared with wild-type BRCA1 human BC cells [46].